Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was.
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis of 49 second- and
Mr. Garland brings significant industry expertise with a long track record of successful launchesSAN FRANCISCO, Oct. 17, 2023 Olema Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical.
Olema Oncology Appoints Oncology Biotech Executive Scott Garland To Board Of Directors menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.